Zionexa

History

2021: GE Healthcare bought Zionexa

In early May 2021, it became known that GE Healthcare bought Zionexa, a late-stage cancer diagnostic tool developer. The company-developed drug Cerianne (fluoroestradiol F-18) is used in PET imaging to detect ER-positive tumors and choose treatment in patients with recurrent or metastatic breast cancer.

Zionexa is a private French company founded in 2018. The state of Zionexa has 24 people working in France and the USA; after the acquisition, they will all move to the GE Healthcare division. In addition to these, GE Healthcare intends to hire about 70 new employees in a pharmaceutical diagnostic team headquartered in Marlborough, Massachusetts.

GE Healthcare acquired Zionexa

Zionexa is known to develop tools to identify oncological and neurological biomarkers. GE Healthcare intends to finalize and market Zionexa's most promising biomarker assays as well as Cerianne's recently FDA-approved PET imaging agent.

Currently, in the treatment of patients with metastatic breast cancer, oncologists choose therapy based on biopsy results. However, expression of estrogen (ER) receptors - one of the most common biomarkers of breast cancer - can vary both within the primary tumor and in metastases. Cerianne expands the diagnostic capabilities of oncologists, allowing you to clarify the diagnosis and select an individualized treatment plan.

The drug Cerianne appeared on the US market in December 2020, and about 25% of the corresponding patient population have access to it. Using its supply chain, market access, and commercial expertise, GE Healthcare's pharmaceutical diagnostics division intends to provide access to the Cerianne drug to 75% of patients with metastatic breast cancer in the U.S. by 2023.^[1]

Notes